Literature DB >> 14532289

Heterodimerization of substance P and mu-opioid receptors regulates receptor trafficking and resensitization.

Manuela Pfeiffer1, Susanne Kirscht, Ralf Stumm, Thomas Koch, Daifei Wu, Magdalena Laugsch, Helmut Schröder, Volker Höllt, Stefan Schulz.   

Abstract

The micro-opioid receptor (MOR1) and the substance P receptor (NK1) coexist and functionally interact in nociceptive brain regions; however, a molecular basis for this interaction has not been established. Using coimmunoprecipitation and bioluminescence resonance energy transfer (BRET), we show that MOR1 and NK1 can form heterodimers in HEK 293 cells coexpressing the two receptors. Although NK1-MOR1 heterodimerization did not substantially change the ligand binding and signaling properties of these receptors, it dramatically altered their internalization and resensitization profile. Exposure of the NK1-MOR1 heterodimer to the MOR1-selective ligand [D-Ala2,Me-Phe4,Gly5-ol]enkephalin (DAMGO) promoted cross-phosphorylation and cointernalization of the NK1 receptor. Conversely, exposure of the NK1-MOR1 heterodimer to the NK1-selective ligand substance P (SP) promoted cross-phosphorylation and cointernalization of the MOR1 receptor. In cells expressing MOR1 alone, beta-arrestin directs the receptors to clathrin-coated pits, but does not internalize with the receptor. In cells expressing NK1 alone, beta-arrestin internalizes with the receptor into endosomes. Interestingly, in cells coexpressing MOR1 and NK1 both DAMGO and SP induced the recruitment of beta-arrestin to the plasma membrane and cointernalization of NK1-MOR1 heterodimers with beta-arrestin into the same endosomal compartment. Consequently, resensitization of MOR1-dependent receptor functions was severely delayed in coexpressing cells as compared with cells expressing MOR1 alone. Together, our findings indicate that MOR1 by virtue of its physical interaction with NK1 is sequestered via an endocytotic pathway with delayed recycling and resensitization kinetics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14532289     DOI: 10.1074/jbc.M307095200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells.

Authors:  Kevin D G Pfleger; Karin A Eidne
Journal:  Biochem J       Date:  2005-02-01       Impact factor: 3.857

Review 4.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

Review 5.  Targeting opioid receptor heterodimers: strategies for screening and drug development.

Authors:  Achla Gupta; Fabien M Décaillot; Lakshmi A Devi
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

6.  Neurokinin 1 and opioid receptors: relationships and interactions in nervous system.

Authors:  Jie Xiao; Si Zeng; Xiangrui Wang; Hasan Babazada; Zhanchun Li; Renyu Liu; Weifeng Yu
Journal:  Transl Perioper Pain Med       Date:  2016

Review 7.  The structural basis of arrestin-mediated regulation of G-protein-coupled receptors.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2006-02-03       Impact factor: 12.310

Review 8.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

9.  Human ACE and bradykinin B2 receptors form a complex at the plasma membrane.

Authors:  Zhenlong Chen; Peter A Deddish; Richard D Minshall; Robert P Becker; Ervin G Erdös; Fulong Tan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

10.  Regulation of the thrombin/protease-activated receptor 1 axis by chemokine (CXC motif) receptor 4.

Authors:  Xianlong Gao; You-Hong Cheng; Garrett A Enten; Anthony J DeSantis; Vadim Gaponenko; Matthias Majetschak
Journal:  J Biol Chem       Date:  2020-08-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.